Retour
64
67
Fourchette du Jour
8,50 €
9,00 €
Fourchette 52 Semaines
5,00 €
13,55 €
Volume
700
Moyenne 50J / 200J
9,74 €
/
11,06 €
Clôture Précédente
9,00 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (626 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 5,5 | 0,4 |
| P/B | 1,5 | 2,9 |
| ROE % | 31,4 | 3,8 |
| Net Margin % | 6,7 | 3,9 |
| Rev Growth 5Y % | 29,7 | 10,0 |
| D/E | 1,8 | 0,2 |
Points Clés
Revenue grew 29,72% annually over 5 years — strong growth
ROE of 31,41% indicates high profitability
Negative free cash flow of -8,00M
P/E of 5,52 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4,62%
Capital efficient — spends only 8,31% of revenue on capex
Croissance
Revenue Growth (5Y)
29,72%
Revenue (1Y)25,10%
Earnings (1Y)13,70%
FCF Growth (3Y)N/A
Qualité
Return on Equity
31,41%
ROIC11,16%
Net Margin6,73%
Op. Margin10,30%
Sécurité
Debt / Equity
1,83
Current Ratio1,57
Interest Coverage5,42
Valorisation
P/E Ratio
5,52
P/B Ratio1,52
EV/EBITDA7,19
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 25,10% | Revenue Growth (3Y) | 23,66% |
| Earnings Growth (1Y) | 13,70% | Earnings Growth (3Y) | 26,28% |
| Revenue Growth (5Y) | 29,72% | Earnings Growth (5Y) | 53,63% |
| Profitability | |||
| Revenue (TTM) | 2,47B | Net Income (TTM) | 166,00M |
| ROE | 31,41% | ROA | 6,71% |
| Gross Margin | 68,42% | Operating Margin | 10,30% |
| Net Margin | 6,73% | Free Cash Flow (TTM) | -8,00M |
| ROIC | 11,16% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1,83 | Current Ratio | 1,57 |
| Interest Coverage | 5,42 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 5,52 | P/B Ratio | 1,52 |
| P/S Ratio | 0,37 | PEG Ratio | 4,96 |
| EV/EBITDA | 7,19 | Dividend Yield | 0,00% |
| Market Cap | 916,19M | Enterprise Value | 1,83B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,47B | 1,97B | 1,61B | 1,22B | 871,20M |
| Net Income | 166,00M | 146,00M | 104,10M | 48,60M | 29,80M |
| EPS (Diluted) | 1,56 | 1,37 | 0,98 | 0,46 | 0,30 |
| Gross Profit | 1,69B | 1,36B | 1,09B | 787,80M | 570,20M |
| Operating Income | 254,00M | 228,50M | 154,80M | 82,30M | 60,00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2,47B | 2,00B | 1,69B | 1,32B | 1,15B |
| Total Liabilities | 1,87B | 1,54B | 1,39B | 1,11B | 1,01B |
| Shareholders' Equity | 603,00M | 454,00M | 297,80M | 210,60M | 139,50M |
| Total Debt | 1,10B | 791,00M | 773,30M | 628,30M | 606,70M |
| Cash & Equivalents | 195,00M | 133,00M | 161,10M | 106,80M | 197,30M |
| Current Assets | 1,08B | 813,30M | 633,40M | 487,60M | 446,00M |
| Current Liabilities | 686,00M | 630,00M | 538,80M | 425,00M | 305,90M |
Scores de Stratégies
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#111 of 616
#66 of 658
Activité Récente
Entré
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entré
Contrarian Investing (David Dreman)
Mar 24, 2026